Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ADAM metallopeptidase domain 3A (ADAM3A) belongs to the ADAM (a disintegrin and metalloproteinase) family, which typically have roles in cell adhesion, migration, proteolysis, and signaling[1][3]. However, ADAM3A is annotated as a pseudogene in humans and does not produce a functional protein[6]. Some other ADAM family members are important proteases involved in ectodomain shedding, reproductive biology (notably in rodents), and disease; however, these functions are not applicable to ADAM3A in humans. Reports regarding ADAM3A typically refer to data from non-human species (e.g., rodents or porcine studies) or are confounded by naming conventions; for example, in rats and pigs, ADAM3a may code for functional proteins involved in sperm-egg interactions[4][5], but this does not apply to humans. In short, ADAM3A is a pseudogene in humans, is not a therapeutic target, and does not have biological or clinical relevance[6]. Any disease associations, drug interactions, or molecular functions attributed to ADAM3A are misplaced, and care should be taken to avoid conflating this "target" with other functional ADAM family members.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ADAM metallopeptidase domain 3A (ADAM3A).